NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals, Inc. manufactures and sells wound care products. The company offers hypochlorous acid for use in the cleansing and irrigation of post-surgical wounds, minor burns, and superficial abrasions. It sells its products to its distribution partners in China. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in F… Read more
NovaBay Pharmaceuticals Inc (NBY) - Total Assets
Latest total assets as of September 2025: $3.49 Million USD
Based on the latest financial reports, NovaBay Pharmaceuticals Inc (NBY) holds total assets worth $3.49 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
NovaBay Pharmaceuticals Inc - Total Assets Trend (2003–2024)
This chart illustrates how NovaBay Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
NovaBay Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
NovaBay Pharmaceuticals Inc's total assets of $3.49 Million consist of 56.5% current assets and 43.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $430.00K | 12.6% |
| Accounts Receivable | $389.00K | 11.4% |
| Inventory | $765.00K | 22.4% |
| Property, Plant & Equipment | $1.01 Million | 29.5% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2003–2024)
This chart illustrates how NovaBay Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NovaBay Pharmaceuticals Inc's current assets represent 56.5% of total assets in 2024, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 12.6% of total assets in 2024, up from 0.0% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is property, plant & equipment at 29.5% of total assets.
NovaBay Pharmaceuticals Inc Competitors by Total Assets
Key competitors of NovaBay Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
NovaBay Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - NovaBay Pharmaceuticals Inc generates 2.86x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - NovaBay Pharmaceuticals Inc is currently not profitable relative to its asset base.
NovaBay Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.00 | 1.15 | 5.03 |
| Quick Ratio | 2.00 | 0.91 | 4.81 |
| Cash Ratio | 1.59 | 0.39 | 0.00 |
| Working Capital | $1.45 Million | $ 295.00K | $ 11.41 Million |
NovaBay Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between NovaBay Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.53 |
| Latest Market Cap to Assets Ratio | 0.81 |
| Asset Growth Rate (YoY) | -62.1% |
| Total Assets | $3.42 Million |
| Market Capitalization | $2.79 Million USD |
Valuation Analysis
Near Book Valuation: The market values NovaBay Pharmaceuticals Inc's assets close to their book value ( 0.81x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: NovaBay Pharmaceuticals Inc's assets decreased by 62.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for NovaBay Pharmaceuticals Inc (2003–2024)
The table below shows the annual total assets of NovaBay Pharmaceuticals Inc from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.42 Million | -62.11% |
| 2023-12-31 | $9.03 Million | -44.91% |
| 2022-12-31 | $16.40 Million | -31.61% |
| 2021-12-31 | $23.98 Million | +57.36% |
| 2020-12-31 | $15.24 Million | +35.81% |
| 2019-12-31 | $11.22 Million | +19.86% |
| 2018-12-31 | $9.36 Million | -7.12% |
| 2017-12-31 | $10.08 Million | -34.47% |
| 2016-12-31 | $15.38 Million | +202.95% |
| 2015-12-31 | $5.08 Million | -32.64% |
| 2014-12-31 | $7.54 Million | -51.84% |
| 2013-12-31 | $15.65 Million | -18.64% |
| 2012-12-31 | $19.23 Million | +20.50% |
| 2011-12-31 | $15.96 Million | +2.88% |
| 2010-12-31 | $15.52 Million | -11.45% |
| 2009-12-31 | $17.52 Million | +25.44% |
| 2008-12-31 | $13.97 Million | -41.61% |
| 2007-12-31 | $23.92 Million | +101.60% |
| 2006-12-31 | $11.87 Million | +233.13% |
| 2005-12-31 | $3.56 Million | +170.87% |
| 2003-12-31 | $1.31 Million | -- |